X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development Research & Development

Judit Makara wins Boehringer Ingelheim’s FENS Award 2014 for Exceptional Research in Neuroscience

Yuvraj_pawp by Yuvraj_pawp
5th October 2015
in Research & Development

This year’s Boehringer Ingelheim FENS Award was granted to Judit Makara from the Institute of Experimental Medicine of the Hungarian Academy of Sciences in Budapest, Hungary.

The biannual Boehringer Ingelheim FENS Research Award is endowed with 25 000 Euro in recognition of outstanding research of young scientists in the field of neuroscience. The award is presented in Milan during the 9th Forum of European Neuroscience 2014 (July 5 – 9, 2014). The prize winner will give a plenary lecture at the meeting.

Judit Makara’s scientific interest has been on the understanding of the mechanisms that determine responses of individual nerve cells and neuronal circuits when their internal and external environment changes. Her particular research focus hereby lies in the elucidation of the local properties of the receiving (dendritic) end of the communicating nerve cells. By combining state of the art two-photon microscopy andimaging, electrophysiology and optogenetic techniques, she was able to identify the underlying dendritic mechanisms determining the response of neurons to patterns of stimulated nerve connections and ultimately detected certain activity patterns of the nerve connections.

The goal is to understand how modulation of these dendritic properties influences information coding in the hippocampus, a brain structure involved in memory formation and learning.

Judit Makara is a medical doctor with a PhD in cellular physiology at the lab of Prof. András Spät at the Department of Physiology of the Semmelweis Medical University in Budapest, Hungary. Between 2003-2006 she worked as a postdoctoral fellow with Prof. Tamás Freund. Subsequently, she spent five years at Janelia Farm Research Campus working in the scientific group of Dr. Jeff Magee. In 2011 she returned to her home country Hungary, where she established her own research group at the Institute of Experimental Medicine of the Hungarian Academy of Sciences in Budapest.

Her working group investigates the regulation of local interactions and integration of synaptic inputs in nerve cells (pyramidal neurons) at the hippocampus. The group explores the role of these effects in the generation of functional neuronal ensembles.

“We are proud of having the opportunity to honour outstanding research of young scientists in Neuroscience for the seventh time now. Judit Makara’s work could contribute to revolutionising our understanding of the complexities of the human brain and propel forward medical developments. It is a pleasure to honour her with the Boehringer Ingelheim FENS Research Award.” said Bernd Sommer, Vice President of Neuroscience Research at Boehringer Ingelheim.

“This recognition is both reassuring and encouraging to continue my research efforts to contribute to our understanding of neuronal functions. We will hopefully one day understand the process of neuronal information encoding and the underlying cellular structures far better and may ultimately be able to explain how learning and comprehension occurs. ” said Dr. Makara receiving the Award Certificate.

Previous Post

35 partners from industry and academia to join European research initiative for the prevention of Alzheimer’s dementia

Next Post

Type 2 Diabetes Research: Connexios Life Sciences and Boehringer Ingelheim Enter Agreement for Novel AMPK Activators

Related Posts

Robots and AI in Drug
Articles

Robots and AI in Drug Discovery Are Transforming Medicine

29th May 2025
Pharmaceutical-Chemicals Market Booms with Rising API Demand
Asia

Pharmaceutical Chemicals Market Booms with Rising API Demand

28th May 2025
Next in Pharma 2025 Innovations
Articles

Next in Pharma 2025: Innovations Shaping the Future

28th May 2025
Insights

Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

27th May 2025
Insights

AstraZeneca Eyes Acquisition To Develop Cell Therapies

24th March 2025
Drug Development

Continuous Bioprocessing Market to Surge by 2028

7th March 2025
Next Post

Type 2 Diabetes Research: Connexios Life Sciences and Boehringer Ingelheim Enter Agreement for Novel AMPK Activators

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In